Consultation on the draft Issue Identification Paper: Drug-device combination products
Current status: Open
Opened for input from May 10, 2021 to July 12, 2021.
Drug-device combination products (DDCPs) are health products that combine one or more drug components with one or more medical device components into one single integrated product. Health Canada is updating its policy on DDCPs to provide more detail and clarity on the classification and regulation of these products. As the first step, an Issue Identification Paper has been drafted to capture the outstanding issues with the current version of the policy.
Join in: how to participate
Review the issue identification paper:
Send us your input by email:
Who is the focus of this consultation
Health Canada aims to engage with:
- health system partners
Key questions for discussion
Through this consultation, Health Canada wants to make sure that key stakeholders:
- are aware of this initiative to update the policy on drug-device combination products
- have the opportunity to identify any concerns they have with the current version of the policy
We are seeking your input on the following themes:
- classifying drug-device combination products
- assigning an appropriate single regulatory pathway
- establishing suitable authorization requirements
The information gathered from this process will help to create a shared understanding of the issues associated with the existing policy and will inform the policy work to support its update.
- Policy on Drug/Medical Device Combination Products
- Policy on Drug/Medical Device Combination Products - Decisions
Contact us by email: firstname.lastname@example.org
Report a problem or mistake on this page
- Date modified: